Executive Vice President, General Counsel, and Secretary · ACADIA PHARMACEUTICALS INC (ACAD)

Austin Kim

A named executive officer of ACADIA PHARMACEUTICALS in every fiscal year CompBrief holds from FY2018 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$4,700,906

Salary $489,042Stock awards $2,975,541

FY2021: $2,330,704

3rd of 5 named executive officers at Acadia Pharmaceuticals by FY2022 total.

5 named officers on file for ACADIA PHARMACEUTICALS, FY2022

Austin Kim’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 7 equity grants, each cited to its filing
  • ACAD’s disclosed peer group of 23 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ACADIA PHARMACEUTICALS’s whole pay program stands against its peers

  • ACADIA PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ACAD→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 1, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Austin Kim’s full pay file as a PDF — free

More than this page: up to 10 years of Austin’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Austin Kim compensation by year

ACADIA PHARMACEUTICALS Summary Compensation Table · all 5 fiscal years held
In US dollars, as ACADIA PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020FY2021FY2022
Salary$195,704$435,913$448,751$470,180$489,042
Bonus$200,000$0$0$0$0
Stock awards$0$603,835$559,355$880,895$2,975,541
Option awards$1,597,106$601,492$561,175$890,573$1,003,216
Non-equity incentive$86,306$225,134$164,832$65,606$228,895
Pension and deferred compensation$0$0$0$0$0
All other$47,096$39,753$13,174$23,449$4,212
Total$2,126,212$1,906,126$1,747,288$2,330,704$4,700,906

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ACADIA PHARMACEUTICALS INC DEF 14A filed May 1, 2023, accession 0000950170-23-015969, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ACADIA PHARMACEUTICALS INC filed document, accession 0000950170-23-015969. Every figure is read from that document and cited to the page and table it appears in. Filed May 1, 2023.

$2.1M
$1.9M
$1.7M
$2.3M
$4.7M
FY18
FY19
FY20
FY21
FY22
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU96,463$1,535,691—
PSU19,092$303,945—
RSU19,092$303,945—
PSU8,855$140,972—
RSU6,642$105,741—
PSU6,533$104,005—
PSU6,010$95,679—
RSU3,267$52,011—
RSU3,005$47,840—
Option6,422—$42.81
Option3,515—$25.12
Option17,663—$49.74

Per the Outstanding Equity Awards at Fiscal Year-End table in ACADIA PHARMACEUTICALS INC's FY2022 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 13 award rows shown.

Insider transactions since the last proxy

11 Form 4 lines since the FY2022 proxy (filed May 1, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2024-01-08Sale—590$29.9646,901
2024-01-06Exercise or conversion—1,634—47,491
2024-01-06Exercise or conversion derivative—1,634$0.000
2023-10-06Sale—16,369$21.9645,857
2023-10-05Exercise or conversion—36,174—62,226
2023-10-05Exercise or conversion derivative—36,174$0.0060,289
2023-05-01Grant or award derivative—18,172$0.0018,172
2023-05-01Sale—917$21.1825,513

The 8 most recent of 11 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

ACADIA PHARMACEUTICALS’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Stephen DavisChief Executive Officer$14,028,139
Srdjan StankovicFormer President$7,797,628
Austin Kim · this pageExecutive Vice President, General Counsel, and Secretary$4,700,906
Mark SchneyerExecutive Vice President, Chief Financial Officer$2,353,204
Brendan TeehanExecutive Vice President, Chief Operating Officer and Head of Commercial$2,297,810

The full ACADIA PHARMACEUTICALS compensation record

free company brief

This page is one person within ACADIA PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ACADIA PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Austin Kim's compensation dossier · One-time report. No refunds.